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Abstract
Background: Apolipoprotein E (apoE) is postulated to affect brain Aβ levels through multiple mechanisms--by altering 
amyloid precursor protein (APP) processing, Aβ degradation, and Aβ clearance. We previously showed that an apoE-
derived peptide containing a double repeat of the receptor-binding region was similarly effective in increasing APP 
processing in vivo. Here, we further examined whether peptides containing tandem repeats of the apoE receptor-
binding region (amino acids 141-149) affected APP trafficking, APP processing, and Aβ production.
Results: We found that peptides containing a double or triple tandem repeat of the apoE receptor-binding region, 
LRKLRKRLL, increased cell surface APP and decreased Aβ levels in PS1-overexpressing PS70 cells and in primary 
neurons. This effect was potentiated by a sequential increase in the number of apoE receptor-binding domain repeats 
(trimer > dimer > monomer). We previously showed that the apoE dimer increased APP CTF in vivo; to determine 
whether the dimer also affected secreted APP or Aβ levels, we performed a single hippocampal injection of the apoE 
dimer in wild-type mice and analyzed its effect on APP processing. We found increased sAPPα and decreased Aβ levels 
at 24 hrs after treatment, suggesting that the apoE dimer may increase α-secretase cleavage.
Conclusions: These data suggest that small peptides consisting of tandem repeats of the apoE receptor-binding 
region are sufficient to alter APP trafficking and processing. The potency of these peptides increased with increasing 
repeats of the receptor binding domain of apoE. In addition, in vivo administration of the apoE peptide (dimer) 
increased sAPPα and decreased Aβ levels in wild-type mice. Overall, these findings contribute to our understanding of 
the effects of apoE on APP processing and Aβ production both in vitro and in vivo.
Background
Alzheimer's disease (AD) is an age-related neurodegen-
erative disease characterized by the progressive loss of
synapses and neurons and by the formation of amyloid
plaques and neurofibrillary tangles [1]. Amyloid plaques
are composed predominantly of the Aβ peptide, a 40 or
42 amino acid cleavage product of the amyloid precur-
sor protein (APP). APP is a synaptic, transmembrane
protein that undergoes extracellular cleavage by one of
two proteases, α- or β-secretase, which results in the
formation of large N-terminal extracellular fragments of
secreted APP (sAPP) and smaller, membrane-bound C-
terminal fragments (CTF). If the initial cleavage event
occurs via β-secretase, then cleavage of the CTF by γ-
secretase in the intramembrane region results in the
formation of Aβ. Mutations in APP and in a component
of the γ-secretase complex (presenilin) cause familial
forms of AD. APP can be preferentially cleaved by α- or
β-secretase depending on its localization within the cell.
The majority of α-secretase activity is thought to occur
on the cell surface [2], whereas β-secretase cleavage and
Aβ production is thought to occur following endocyto-
sis of APP in the endosomal pathway [3]. Understanding
APP function, trafficking, and processing in neurons
may provide valuable information in generating inter-
ventions against AD pathogenesis and its accompanying
memory loss.
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ApoE is the major genetic risk factor for AD (reviewed
in Roses, 2006 [4]) and is known to directly bind Aβ and
co-localize with cerebral amyloid deposits in AD patients
[5-8]. However, the mechanism by which apoE and its
receptors affect the risk for AD remains unknown. Some
possible effects of apoE include altering APP processing
[9], facilitating internalization and degradation of Aβ [10-
13], improving clearance of Aβ into the periphery [14],
and altering neuronal toxicity of Aβ [15]. However, some
studies show detrimental effects of apoE where apoE
facilitates Aβ oligomerization [16,17]. Some of the con-
trasting evidence may be attributed to the different iso-
forms of apoE: human apoE2 reduces brain Aβ burden in
transgenic APP mice, while human apoE4 increases brain
Aβ burden [18]. These isoform specific effects were also
seen in APP transgenic mice expressing human apoE,
where Aβ deposition was greatest in apoE4 APP trans-
genic mice compared to apoE3 and apoE2 [19,20].
Recombinant human apoE at physiological levels (100
n M )  h a s  b e e n  r e p o r t e d  t o  d e c r e a s e  A β  p r o d u c t i o n  i n
CHO-APP751, HEK293, and primary neuron cells [21].
However, other studies show that lipid deficient apoE4 in
APP-overexpressing rat neuroblastoma B103 cells
increased Aβ production compared to lipid deficient
apoE3 [22], and apoE binding to apoEr2 promoted APP
endocytosis, increasing Aβ production [23]. Thus, there
is no consensus yet about how apoE affects APP process-
ing.
We and others [24-26] have used a derivative of apoE, a
small peptide containing a tandem repeat of the receptor
binding domain, to show the effects of apoE on neuronal
signaling and APP processing. We found that apoE-
derived peptide treatment increased ERK and decreased
JNK activation in primary neurons [27]. In addition, the
apoE-derived peptide significantly reduced inflamma-
tion in several animal models of disease [28,29], which
may occur through the apoE peptide-induced decrease in
c-Jun N-terminal kinase-mediated microglial activation
[30]. Furthermore, we chronically administered the apoE-
derived peptide via osmotic pump and observed a consis-
tent effect on apoE signaling, as well as on APP process-
ing, in vivo [25]. These data implicate a role for the apoE-
derived peptide, regardless of isoform, in various signal-
ing processes in neurons and glia, and these signaling
processes may be related to our observed effects on
altered APP processing.
In the present study, we investigated the importance of
the tandem repeat in the apoE-derived peptide, and the
ability of this peptide to affect APP trafficking, APP pro-
cessing, and Aβ levels. We first demonstrate that a tan-
dem repeat in the apoE-derived peptide is necessary to
effect cell surface APP levels. We then show that apoE-
derived peptides decrease secreted Aβ in PS1-overex-
pressed PS70 cells and in primary neurons. Again, the
effect of the monomer was minimal in reducing secreted
Aβ levels in both systems, whereas the dimer and trimer
show a clear dose response. The potency of the apoE-
derived peptides follows the order: trimer > dimer >
monomer, which correlates with the stability of their
alpha helical secondary structure as determined compu-
tationally. The effect of the dimer on APP processing was
further evaluated in vivo, where a single hippocampal
injection of the apoE-derived dimer peptide resulted in a
significant increase in sAPPα and a significant decrease
in soluble Aβ1-40 levels in wild-type mice, suggesting
that the apoE dimer may promote α-secretase cleavage.
Our data demonstrate a clear effect of the apoE-derived
dimer peptide on APP trafficking, processing, and Aβ
levels both in vitro and in vivo.
Results
Characterization of apoE peptides
ApoE-derived peptides have been found in several stud-
ies, including our own, to be involved in reducing inflam-
mation and in increasing APP processing [25,26,30]. This
peptide sequence was derived from the receptor-binding
domain of apoE (LRKLRKRLL). In our previously pub-
lished studies, we used an apoE-derived peptide that con-
sisted of a tandem repeat of this sequence, labeled as the
dimer in this study (Table 1). To test the importance of
the tandem repeat of the apoE-derived mimetic peptide
in affecting APP processing and Aβ production, we also
synthesized the single LRKLRKRLL sequence denoted as
the monomer, and the triple tandem repeat, (LRKL-
RKRLL)3, denoted as the trimer (Table 1).
Based on the structure of the apoE receptor binding
domain, we hypothesized that these peptides could exist
as alpha helices with varying degrees of stability, which
may result in differences in binding efficacy. Therefore, a
computational study was employed to determine the rela-
tive stability of the three apoE-derived peptides as alpha
helices. As shown in Table 2, the alpha helical structure of
the trimer is considerably more stable than the dimer by
approximately 2.4 kcal/mol, and the alpha helical struc-
ture of the dimer is more stable than the monomer by
approximately 2.0 kcal/mol.
The propensity of the LRKLRKRLL motif to form alpha
helices was further investigated by a search through the
Table 1: Amino acid sequences of the apoE-derived 
peptides used.
Peptide Sequence
Monomer LRKLRKRLL
Dimer LRKLRKRLLLRKLRKRLL
Trimer LRKLRKRLLLRKLRKRLLLRKLR
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Dihedral Angle and Secondary Structure Database of
Short Amino Acid Fragments (DASSD). [REFERENCE:
Dayalan S, Gooneratne ND, Bevinakoppa S, Schroder H:
Dihedral angle and secondary structure database of
short amino acid fragments Bioinformation 2006, 1:78-
80] The DASSD database stores the dihedral angles and
the secondary structure details of short amino acid frag-
ments derived from 5,227 non-redundant protein struc-
tures with less than 2 Å resolution. A search of the LRK
motif revealed that 222 out 311 structures (71%) in the
DASSD database contained the LRK motif in alpha heli-
ces according to STRIDE classification. Similarly, a search
of the RLL motif revealed that 300 out of 476 structures
(63%) contained this sequence in an alpha helix. A repre-
sentative sample of unique structures that contain these
motifs in alpha helical structures are given by the follow-
ing PDB codes: 1EWK, 1YKE, 2CWY, 1WUD, 1CII,
2GHJ, 3KS9, 2QR4, and 1TTY. This supports our
hypothesis that the LRK and RLL motifs in our apoE-
derived peptides have propensities toward forming alpha
helical structures.
ApoE dimer is not toxic to PS70 cells or primary neurons
In order to first test the potential toxicity of our com-
pounds, we treated PS70 cells (a PS1-overexpressing cell
line which produces high levels of Aβ) with PBS control
or increasing doses of the apoE-derived peptide dimer
(30 nM, 300 nM, 1 uM, 3 uM) for 24 h and conducted an
MTT assay to evaluate for cell viability. We found that
there was no toxicity of the peptide compared to control
at any concentration tested (Fig. 1A). We also tested for
toxicity of this compound in primary neuronal cells.
Again, we did not observe any toxicity at any of the con-
centrations tested compared to control (Fig. 1B).
ApoE dimer and trimer promote surface levels of APP in 
COS7 cells
Trafficking of APP to the cell surface may be important
for effects on APP processing, as specific secretases are
known to be distinctly localized within the cell. β- and γ-
secretases are predominantly present intracellularly in
endosomes, and α-secretase is active at the cell surface
[31,32]. To examine the effects of apoE peptides on cell
surface levels of APP, we transfected COS7 cells with APP
and treated cells with control, 1 μM monomer, 1 μM
dimer, or 1 μM trimer for 24 h. Cell surface proteins were
biotin labeled, isolated with avidin beads, and immunob-
lotted for APP. Monomer treatment caused a non-signifi-
cant 12% increase in cell surface levels of APP (Fig. 2A
&2B). The dimer and the trimer treatments significantly
increased cell surface levels of APP by 98% and 197%,
respectively (Fig. 2C-F). Levels of cell β-actin were consis-
tent across conditions, serving as a loading control (Fig.
2A-C, bottom panels). These data suggest that the tan-
dem repeat of the receptor-binding region of apoE is nec-
essary for our apoE-derived peptides to affect APP
trafficking.
ApoE-derived peptides increase cell surface APP in primary 
cortical and hippocampal neurons
To test whether the apoE mimetic peptides regulate
endogenous APP trafficking in primary cortical neuronal
cells, we treated cells with control (PBS) or 1 μM apoE
monomer for 24 hrs. Cell surface proteins were biotiny-
lated, isolated with avidin beads, and immunoblotted for
Figure 1 ApoE-derived peptide does not affect cell viability in 
PS70 or primary neuronal cells. A. PS70 cells overexpressing PS1 
were treated with apoE dimer at various concentrations for 24 h and 
cell viability was assayed (n = 6). ApoE dimer treatment did not result 
in cell toxicity at any of the indicated concentrations. B. Primary neu-
rons were treated with apoE dimer at various concentrations for 24 h 
and cell viability was assayed (n = 6). ApoE dimer treatment did not re-
sult in cell toxicity at any of the indicated concentrations.
Table 2:  E values for monomer, dimer, and trimer apoE-
derived peptides. 
Peptide E (kcal/mol)
Monomer 6.75
Dimer 8.77
Trimer 11.21
Energy change of each structure was computed by molecular 
simulations as described.Minami et al. Molecular Neurodegeneration 2010, 5:16
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APP with antibody 22C11. ApoE monomer did not alter
cell surface levels of APP (Fig. 3A-B).
We also examined the effect of apoE dimer and trimer
on surface APP levels in cultured cortical neurons by
treating with 1 μM apoE dimer or trimer for 24 hrs and
found increased surface levels of endogenous APP after
24 hrs of apoE dimer (by 72%, n = 3, p < 0.01) and trimer
(by 166%, n = 3, p < 0.001) treatment (Fig. 3C-D). These
results are consistent with those obtained in COS7 cells
(Fig. 2), where we observed an effect of apoE dimer and
trimer, but not monomer, on increased cell surface APP
levels.
Figure 2 ApoE-derived peptide regulates APP trafficking in COS7 cells. COS7 cells were transiently transfected with APP and treated with control 
or apoE monomer (n = 3, A), apoE dimer (n = 3, C), or apoE trimer (n = 3, E) for 24 h. Total APP and β-actin levels in cell lysates were measured for 
loading control (lower panels). Quantification of biotin-labeled cell surface APP in COS7 cells showed a 12% (B), 98% (D), and 197% (F) increase in 
surface APP by the apoE monomer (NS: no significant), dimer, and trimer, respectively (n = 3, *p < 0.01). Levels of β-actin in the cell lysate were con-
sistent across conditions (bottom panels).Minami et al. Molecular Neurodegeneration 2010, 5:16
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To further test whether the apoE mimetic peptides reg-
ulate APP trafficking in primary hippocampal neurons,
we transfected hippocampal neurons with N-terminal
GFP-tagged APP and treated cells with control or 1 μM of
the apoE monomer, dimer, or trimer for 24 h. Transfec-
tion of cells with APP allowed us to measure surface APP
by live cell immunostaining. The dimer and trimer treat-
ments significantly increased cell surface levels of APP
(Fig. 3E, third and fourth panels). Quantification of these
data showed significant 21% and 43% increases in surface
APP by the dimer and trimer in primary hippocampal
neuronal cells, respectively (n = 10, *p < 0.05, *p < 0.01,
Figure 3 ApoE-derived peptide affects APP trafficking in primary cortical and hippocampal neuronal cells. A. Cultured cortical neuronal cells 
were treated with control (PBS) or apoE monomer (n = 3, 1 μM for 24 hr). Cell surface proteins were biotinylated, isolated with avidin-conjugated 
beads, and immunoblotted with 22C11 antibody against rodent APP. Total APP and β-actin in cell lysates were measured in the bottom panel. B. 
Quantification of biotin-labeled cell surface APP in primary cortical neurons showed no significant change by apoE monomer compared to control. 
C. Cultured cortical neuronal cells were treated with control (PBS), apoE dimer, or apoE trimer (n = 3, 1 μM for 24 hr). Total APP and β-actin in cell lysates 
were measured in the bottom panel. D. Quantification of biotin-labeled cell surface APP showed a 72% (p < 0.01, n = 3) and 166% (p < 0.001, n = 3) 
increase in surface APP by the apoE dimer and trimer, respectively. Error bars indicate SEM. E. Cultured hippocampal neurons were transfected at 
DIV12 with GFP conjugated APP. At DIV 14 cells were treated with PBS control or the apoE monomer (n = 10, 1 μM), dimer (n = 10, 1 μM), or trimer (n 
= 10, 1 μM) for 24 h, and surface APP was measured by live cell staining. F. Quantification of surface APP intensity in (A) showed a 21% and 43% increase 
by the dimer and trimer, respectively (n = 10, *p < 0.05, *p < 0.01).Minami et al. Molecular Neurodegeneration 2010, 5:16
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Fig. 3F). These data are consistent with our cell surface
biotinylation results, and support a role for apoE dimer
and trimer peptides in altering APP trafficking.
ApoE-derived peptides significantly decrease Aβ levels in 
PS70 cells
The above data suggest that the apoE mimetics may
decrease β-cleavage of APP by changing APP trafficking
to favor α-cleavage. To directly test whether the apoE-
derived peptide analogs could affect Aβ production, we
treated a human PS1-overexpressing cell line (PS70) with
the apoE mimetic peptides at various concentrations (30
nM to 3 μM) for 24 h and measured Aβ1-40 levels from
the conditioned media by ELISA. We found that treat-
ment with the apoE monomer resulted in small but sig-
nificant decreases in Aβ1-40 compared to control (20%
decreases at 30 nM and 100 nM (p < 0.05); 30% decreases
at 300 nM, 1 μM, and 3 μM (p < 0.01) (n = 7 for all con-
centrations except 3 μM, n = 5) (Fig. 4A)). The dimer and
trimer resulted in larger significant dose-dependent
decreases in Aβ1-40 (dimer: 35% decrease at 30 nM (p <
0.01); 51% decrease at 100 nM; 64% decrease at 300 nM;
77% decrease at 1 μM; 90% decrease at 3 μM (each p <
0.001); trimer: 68% decrease at 100 nM; 72% decrease at
500 nM; 85% decrease at 1 μM (each p < 0.001) (n = 6 for
all dimer concentrations and for the control trimer; n = 4
for all concentrations of the trimer) (Fig. 4B-C)). Again,
we observed a consistent effect where the monomer was
least effective and the trimer was most effective in reduc-
ing Aβ1-40 levels. These data suggest that increasing the
number of tandem repeats of the receptor binding
domain increases the potency of the apoE mimetic pep-
tides in lowering Aβ. We performed a control experiment
to demonstrate that the apoE peptide did not interfere
with the ELISA assay, and found that measurement of
human Aβ1-40 was not different in the presence of PBS
or apoE dimer peptide (Fig. 4D).
ApoE-derived peptides significantly decrease Aβ levels in 
primary neuronal cells
In order to determine whether the apoE peptide could
affect Aβ production in a more relevant system, we
treated primary neuronal cells (DIV 14) with various con-
centrations of the apoE peptides (monomer, dimer, or
trimer) and measured rodent Aβ1-40 by ELISA after 24 h.
Treatment with the apoE monomer did not result in sig-
nificant decreases in Aβ1-40 (Fig. 5A) (n = 5), but treat-
ment with the apoE dimer and trimer resulted in
significant dose-dependent decreases in Aβ1-40 (dimer:
19% decrease at 500 nM (p < 0.05); 27% decrease at 1 μM
(p < 0.01) (n = 5) (Fig. 5B); trimer: 12% decrease at 100
nM (p < 0.05); 18% decrease at 500 nM (p < 0.05); 28%
decrease at 1 μM (p < 0.001) (n = 5) (Fig. 5C)). As with
our previous experiment, we performed a control experi-
ment to demonstrate that the apoE peptide did not inter-
fere with the ELISA assay, and found that measurement
of rodent Aβ1-40 was not different in the presence of PBS
or apoE dimer peptide (Fig. 5D).
ApoE-derived peptide increases secreted APPα and 
decreases Aβ production in vivo
We have thus far demonstrated that the apoE dimer regu-
lates APP trafficking and Aβ production in vitro; to test
whether the dimer affected endogenous APP proteolysis
in vivo, we injected PBS control or a 10 mM solution of
the dimer (in a 2 μL volume) into the hippocampus of
wild-type mice. After 4 h or 24 h, we dissected the tissue
surrounding the injection site from each brain and mea-
sured endogenous rodent sAPPα and sAPPβ by western
blot. We found that sAPPα was not altered at 4 h, but was
significantly increased by 77% at 24 h by the dimer com-
Figure 4 ApoE-derived peptides significantly decrease Aβ1-40 levels in PS70 cells. PS70 cells were treated with the apoE monomer (n = 6, A), 
dimer (n = 6, B), or trimer (n = 6, C) for 24 h at various concentrations. Aβ1-40 levels in the conditioned media were determined by ELISA (n = 6). The 
apoE monomer decreased Aβ1-40 by 20% at 30 nM and 100 nM (p < 0.05) and by 30% at 300 nM, 1 μM, and 3 μM (p < 0.01). The apoE dimer decreased 
Aβ1-40 by 35% at 30 nM (p < 0.01), 51% at 100 nM, 64% at 300 nM, 77% at 1 μM, and 90% at 3 μM (p < 0.001 for all). The apoE trimer decreased Aβ1-
40 by 68% at 100 nM, 72% at 500 nM, and 85% at 1 μM (p < 0.001 for all). D. Human Aβ1-40 was measured from samples containing the apoE dimer 
peptide alone, synthetic human Aβ40 alone, synthetic human Aβ40 with PBS, or synthetic human Aβ40 with apoE dimer peptide. Aβ1-40 values were 
normalized to background with apoE dimer peptide alone, and were not found to be significantly different in the presence of PBS or apoE dimer pep-
tide.Minami et al. Molecular Neurodegeneration 2010, 5:16
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pared to controls (Fig. 6A &6B, upper panel, n = 6). We
did not find significant differences in sAPPβ compared to
controls (Fig. 6A &6C, second panel, n = 6). β-actin load-
ing controls were consistent across samples (Fig. 6A, bot-
tom panel).
We did not observe a significant difference in Aβ40 lev-
els in mice treated with 10 mM apoE dimer at 4 hrs or 24
hrs (data not shown). To test whether a lower, more phys-
iologically relevant, concentration of the dimer affected
endogenous Aβ production in vivo, we injected 1 mM or
10 mM solutions of the dimer (in a 2 μL volume) into the
hippocampus of wild-type mice. We analyzed endoge-
nous rodent Aβ1-40 by ELISA (Fig. 6D). We found that
Aβ1-40 was significantly decreased by 40% with the 1
mM apoE dimer injection after 24 h treatment (n = 9)
compared to controls (PBS, n = 9) (Fig. 6D). We found a
similar, but not statistically significant, decrease in Aβ1-
40 with the 10 mM apoE dimer injection after 24 h (n =
8). We also tested whether endogenous rodent Aβ1-42
levels were altered with treatment. We did not observe
any significant difference in Aβ1-42 levels following apoE
peptide treatment at 1 mM or 10 mM (Fig. 6E). To test
whether the dimer interfered with rodent Aβ1-42 ELISA
detection, we assayed for rodent Aβ1-42 in the presence
of PBS or apoE dimer peptide and found no significant
difference compared to Aβ1-42 alone (Fig. 6F). These
data suggest that a single 1 mM injection of apoE dimer
lowers endogenous Aβ1-40 production in vivo.
Discussion
I n  t h e s e  s t u d i e s,  w e  t e s t e d  w h e t h e r  s i n g l e  ( m o n o m e r ) ,
double (dimer), or triple (trimer) repeats of the receptor-
binding domain of apoE had an effect on Aβ levels in
vitro and in vivo and whether this effect was accompanied
by changes in APP trafficking or processing. We showed
that the apoE dimer and trimer increased cell surface
APP levels in vitro (Fig. 2 &3). We also observed a dose-
dependent decrease in secreted Aβ levels from PS70 cells
and primary neurons treated with either dimer or trimer
(Fig. 4 &5). Finally, we found an in vivo effect of apoE
dimer treatment, where we observed increased sAPPα
and decreased Aβ at 24 hours following a single hip-
pocampal injection of the apoE dimer (Fig. 6). These data
support the idea that the apoE receptor-binding domain,
especially in either double or triple tandem repeat form,
significantly increases cell surface APP and secretion of
sAPPα, and decreases Aβ levels.
Previous studies have implicated a role for apoE, and
the apoE mimetic peptide, in modulating APP processing
by increasing APP CTFs both in vitro and in vivo [21,25].
We hypothesized that regulation of APP trafficking could
mediate this effect, and found that the apoE dimer and
trimer increased cell surface levels of APP in vitro (Fig. 2
& 3 ) .  T h i s  i n c r e a s e  i n  c e l l  s u r f a c e  A P P  c o u l d  l e a d  t o
r e d u c e d  a v a i l a b i l i t y  o f  A P P  t o  c l e a v a g e  b y  β -  a n d  γ -
secretases, which are predominantly present in early
endosomes and may promote α-secretase cleavage,
resulting in the previously observed increase in APP
CTFs and decrease in Aβ production.
Full-length apoE has been shown to decrease secreted
Aβ levels in vitro [21], and here, we show that the apoE
monomer, dimer, and trimer were sufficient to lower Aβ
levels in human PS1-overexpressing PS70 cells (Fig. 4).
Although the apoE monomer efficiently reduced Aβ lev-
els, it was much less effective than the apoE dimer or
trimer. The apoE dimer and trimer induced a significant
dose-dependent decrease in Aβ, and the apoE trimer fur-
ther reduced secreted Aβ levels compared to the apoE
dimer. We observed a similar, albeit less dramatic,
decrease in rodent Aβ from primary hippocampal neu-
rons (Fig. 5). This decrease was most apparent in
response to the apoE trimer, less so in response to the
Figure 5 ApoE-derived peptides significantly decrease Aβ1-40 levels in primary cortical neuronal cells. Primary cortical neurons were treated 
with apoE monomer (n = 6, A), dimer (n = 6, B), or trimer (n = 6, C) for 24 h, and Aβ1-40 levels in the conditioned media were determined by ELISA (n 
= 6). Treatment of primary neurons with apoE dimer decreased Aβ1-40 by 19% at 500 nM (p < 0.05) and 27% at 1 μM (p < 0.01). Treatment with apoE 
trimer decreased Aβ1-40 by 12% at 100 nM (p < 0.05), 18% at 500 nM (p < 0.05), and 28% at 1 μM (p < 0.001). D. Rodent Aβ1-40 was measured from 
samples containing the apoE dimer peptide alone, synthetic rodent Aβ40 alone, synthetic rodent Aβ40 with PBS, or synthetic rodent Aβ40 with apoE 
dimer peptide. Aβ1-40 values were normalized to background with apoE dimer peptide alone, and were not found to be significantly different in the 
presence of PBS or apoE dimer peptide.Minami et al. Molecular Neurodegeneration 2010, 5:16
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Figure 6 ApoE-derived peptide affects APP processing and Aβ production in vivo. A. sAPPα was measured from wild-type mice injected with 
vehicle control (C) for 4 h (n = 6), apoE dimer (D) for 4 h (n = 6) or apoE dimer (D) for 24 h (n = 6). Wild-type mice showed an increase in sAPPα after 
24 h and a slight increase in sAPPα after 4 h compared with control treated mice. B. Quantification of experiments demonstrated that injection with 
the apoE dimer significantly increased sAPPα by 77% after a single injection (*p < 0.01). C. Quantification of experiments demonstrated that injection 
with the apoE dimer did not alter sAPPβ. D. Aβ1-40 was measured from wild-type mice injected with PBS for control (n = 9), or apoE dimer at 1 mM 
(n = 9) or 10 mM (n = 8) for 24 h. ApoE dimer-treated mice showed a 40% decrease in Aβ1-40 at 1 mM after 24 h and a slight 26% decrease in Aβ1-40 
at 10 mM after 24 h compared with control-treated mice. E. Aβ1-42 was measured from the same animals and was not significantly different in either 
1 mM or 10 mM injected animals compared to control. F. Rodent Aβ1-42 was measured from samples containing the apoE dimer peptide alone, syn-
thetic rodent Aβ42 alone, synthetic rodent Aβ42 with PBS, or synthetic rodent Aβ42 with apoE dimer peptide. Aβ1-42 values were normalized to back-
ground with apoE dimer peptide alone, and were not found to be significantly different in the presence of PBS or apoE dimer peptide.Minami et al. Molecular Neurodegeneration 2010, 5:16
http://www.molecularneurodegeneration.com/content/5/1/16
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apoE dimer, and not significant in response to the apoE
monomer. We hypothesize that we were able to observe a
much greater effect in PS70 cells due to the abundant lev-
els of APP and Aβ in this system. Our investigation of
endogenous Aβ production in primary neurons demon-
strates an important effect of apoE peptide on Aβ pro-
duction in the absence of overexpression. In addition, the
data from both PS70 cells and primary neurons are con-
sistent in supporting the idea that additional repeats of
the receptor-binding domain significantly increase the
effect of the apoE-derived peptides on lowering secreted
Aβ levels, as well as on increasing APP trafficking.
Thus, we hypothesize that increasing the number of
residues confers greater stability of the alpha helical
structure, which results in a more rigid conformation and
consequently reduced overall energy for binding. Com-
putational analyses revealed that the stability of the alpha
helix of the apoE-derived peptides are on the order of
trimer > dimer > monomer, where the trimer is 2.4 kcal/
mol more stable than the dimer and the dimer is 2.0 kcal/
mol more stable than the monomer. Further structural
analyses including NMR spectroscopy, x-ray crystallogra-
phy, and circular dichroism spectroscopy should be
employed in future studies to determine the three-
dimensional structure of these peptides and test the
hypothesis that increasing the number of receptor bind-
ing domain repeats increases the alpha helical nature of
the peptide. Alternatively, we hypothesize that multiple
receptor-binding domains may increase the ability of the
peptide to bind multiple ligands, thus increasing its effect
on APP trafficking and processing. However, these possi-
bilities are not mutually exclusive, as increased stability of
the alpha helix may contribute to the peptide binding
multiple ligands.
Importantly, when we tested whether the apoE-derived
peptide affected APP processing and Aβ levels in vivo, we
found that 24 hours of treatment with the apoE dimer
resulted in a significant increase in sAPPα levels (Fig. 6A).
sAPPβ levels were unchanged (Fig. 6C); however, we
observed a significant decrease in soluble Aβ1-40, but not
Aβ1-42, levels following treatment with the apoE dimer
(Fig. 6D). We hypothesize that we were not able to detect
significant differences in Aβ1-42 due to the low levels of
endogenous Aβ1-42 produced in the wild-type mouse. It
will be interesting for future studies to determine
whether apoE peptides can alter Aβ1-42 in APP overex-
pressing mice. It is important to note that at least two
mechanisms contribute to the total measured levels of
soluble Aβ--one involving APP processing and Aβ pro-
duction, and the other involving Aβ degradation and
clearance [12,14]. Here, we show that the apoE-derived
peptide dimer affects α-secretase cleavage of APP as well
as Aβ levels in vivo. However, the observed decrease in
Aβ could be due to either or both apoE-mediated altera-
tions in APP processing and Aβ clearance. Full-length
apoE has been shown to effectively internalize and
degrade Aβ through neurons and microglia [11,33]. Thus,
our data suggest that the major mechanism underlying
apoE-mediated Aβ lowering may involve alterations to
APP trafficking and α-secretase processing.
Conclusions
In summary, we provide data supporting a role for an
apoE mimetic peptide in increasing trafficking of APP to
the cell surface, increasing α-secretase cleavage of APP,
and decreasing Aβ levels in vitro and in vivo, which is
facilitated by the presence of multiple receptor-binding
tandem repeats. These data implicate new roles for apoE
in APP trafficking as well as in APP processing, and pro-
vide further evidence that apoE, regardless of isoform,
decreases Aβ levels in wild-type mice. In addition, the
present study provides new insight regarding the struc-
ture-based action of apoE on APP trafficking and pro-
cessing and Aβ production.
Methods
Chemicals
The apoE-derived peptides consist of the monomer
(LRKLRKRLL), the dimer (LRKLRKRLLLRKLRKRLL),
and the trimer (LRKLRKRLLLRKLRKRLLLRKL-
RKRLL). The monomer represents the receptor-binding
region of apoE (amino acids 141 through 149), and the
dimer and trimer represent double and triple tandem
repeats of the monomer, respectively. The peptides were
synthesized by standard solid phase peptide synthesis
(SPPS) with acetylation of the N-terminus and amidation
at the C-terminus. Synthesis of the peptides was con-
tracted through Biomatik USA, LCC (Wilmington, DE).
The dimer peptide has signaling properties comparable
to full-length apoE (Tolar et al., 1999), and does not con-
tain amino acids that differ between apoE isoforms. We
used antibody 6E10 (Signet) for detecting cell surface
APP and C1/6.1 (from Dr. Paul Matthews) for total APP
in biotinylation experiments. We used an APP N-termi-
nal antibody (Sigma) to detect surface APP in live cell
surface staining experiments. Antibody clone 2B3 (IBL,
Gunma, Japan) was used to detect sAPPα, a rabbit poly-
clonal sAPPβ antibody was used to detect wild-type
sAPPβ (IBL), and monoclonal β-actin antibody (sigma)
was used to confirm loading control.
Computation Methods
The monomer, dimer and trimer structural models were
based primarily on the x-ray structure of apoE
(PDB:1GS9). The E values indicate the energy change of
each structure after energy minimization. The apoE
monomer, dimer and trimer were energy minimized
using consistent valence force field (CFF91) with theMinami et al. Molecular Neurodegeneration 2010, 5:16
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default partial atomic charges available in Discover,
Insight II (Accelrys Inc.). The cutoff for nonbonded inter-
action energies was set to ∞ (no cutoff). To avoid unreal-
istic movements of the peptide caused by computational
artifacts, the structures were relaxed gradually. Each min-
imization was conducted in two steps, first using steepest
descent minimization for 200 cycles and then using con-
jugate gradient minimization until the average gradient
fell below 0.01 kcal/mol.
Cell Lines and Culture Conditions
COS7 (monkey kidney) cells or PS70 (Chinese hamster
ovarian (CHO) cells overexpressing wild-type human PS1
and producing high levels of Aβ [34]) cells were used for
our experiments. Cells were maintained in Opti-MEM
(Invitrogen) with 10% fetal bovine serum (Invitrogen) in
a 5% CO2 incubator. COS7 cells were transiently trans-
fected with 0.5-1 μg of plasmid in FuGENE 6 (Roche
Applied Science) according to the manufacturer's proto-
col and cultured 24 h in Dulbecco's modified Eagle's
medium containing 10% fetal bovine serum. After 24 h
the cells were transferred to Opti-MEM serum-free
media (Invitrogen) and treated with indicated apoE pep-
tides. Cells were collected 24 h later for subsequent analy-
ses.
MTT Assay
MTT assay was performed in either PS70 cells or primary
cortical neurons. 1 mg/ml MTT solution was prepared in
PBS and 50 μl of this solution and 200 μl of DMEM with-
out phenol red were added into each well. Cells were
incubated for 4 hours at 37°C with 5% CO2. After 4 hours,
the MTT solution was removed and replaced with 200 μl
DMSO and 25 μl Sorenson's glycine buffer (glycine 0.1 M,
NaCl 0.1 M, pH:10.5). The plate was further incubated for
5 min at room temperature, and the optical density (OD)
was determined using a plate reader at a test wavelength
of 570 nm and a reference wavelength of 630 nm.
Cell surface biotinylation
COS7 cells were cultured 24 h in Opti-MEM containing
10% fetal bovine serum, then transferred to Opti-MEM
serum-free media and treated with indicated apoE pep-
tides. After 24 h, cells were washed twice with phosphate-
buffered saline, and surface proteins were labeled with
Sulfo-NHS-SS-Biotin, 500 μl at 500 μg/ml phosphate-
buffered saline (Pierce) under gentle shaking at 4°C for 30
min. 50 μl of quenching solution (Pierce) was added to
cells at 4°C, which were washed twice with Tris-buffered
saline. Cells were lysed in 500 μl of lysis buffer, collected
with a cell scraper, disrupted by sonication on ice, incu-
bated for 30 min on ice, and clarified by centrifugation
(10,000 × g, 2 min). To isolate biotin-labeled proteins,
lysate was added to immobilized NeutroAvidin TM Gel
(50 μl) and incubated for 1 h at room temperature. Gels
were washed 5 times with wash buffer and incubated for
1 h with SDS-PAGE sample buffer including 50 mm
dithiothreitol. Surface proteins were then analyzed by
immunoblotting.
Primary Neuronal Culture and Cell Surface Immunostaining
Primary hippocampal or cortical neurons from E18-19
Sprague-Dawley rats were cultured at 150 cells/mm2 as
described (17). Neurons were transfected with GFP con-
jugated APP at 10-12 days in vitro by calcium phosphate
precipitation (4-5 μg of DNA/well). 2 days after transfec-
tion, cells were treated with apoE peptides for 24 h, and
cell surface expression levels of APP were analyzed. Sur-
face immunostaining was performed as described previ-
ously (18). Briefly , live neuron cultures were incubated
with anti-APP N terminal antibody (10 μg/ml in condi-
tioned medium) for 10 min to specifically label surface
APP, then lightly fixed for 5 min in 4% paraformaldehyde
(non-permeabilizing conditions). After fixation, the sur-
face-remaining antibody labeled APP was measured with
Alexa Fluor 555-linked α-rabbit secondary antibodies for
1 h. Images were collected using a Zeiss LSM510 confocal
microscope (Carl Zeiss, Thornwood, NY). Confocal z-
series image stacks encompassing entire neurons were
analyzed using Metamorph software (Universal Imaging
Corp., Downingtown, PA) (18).
In vivo analysis of APP fragments
Mouse brains were homogenized in a 10× volume of 50
mM Tris-HCl buffer, pH 7.6, containing 250 mM sucrose
and protease inhibitor cocktail (Sigma, St. Louis, MO).
Soluble APP and Aβ were extracted in 0.4% DEA, as pre-
viously described (Nishitomi et al., 2006) Briefly, crude
10% brain homogenate was mixed with an equal volume
of 0.4% DEA, sonicated, and ultracentrifuged for 1 hour
at 100,000 × g. The supernatant was collected and neu-
tralized with 10% 0.5 M Tris base, pH 6.8. The resulting
DEA fraction was used for Western blot and ELISA anal-
yses.
Aβ ELISAs
Levels of endogenous full-length mouse Aβ1-40 from the
media from primary neurons or wild-type brain DEA
fractions were quantified using sandwich ELISA as previ-
ously described (Nishitomi et al., 2006). Briefly, a 96-well
plate (Maxisorp) was coated with an anti-Aβ40 antibody,
clone 1A10, overnight at 4°C. After blocking for 2 hrs,
standards (synthetic mouse Aβ peptide 1-40) and samples
were loaded and incubated overnight at 4°C. The plate
was incubated with HRP-coupled detection antibody,
14F1, and visualized using a 3,3',5,5'-tetra methyl benzi-
dine (TMB) substrate. Rodent Aβ1-42 levels were mea-Minami et al. Molecular Neurodegeneration 2010, 5:16
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sured from wild-type brain DEA fractions by an ELISA
kit purchased from Invitrogen (Carlsbad, CA).
Human Aβ1-40 levels were measured from the media
of PS70 cells using sandwich ELISA as previously
described (Horikoshi et al., 2004), using anti-Aβ40 anti-
body clone 1A10 as the capture antibody and antibody
clone 82E1 as the detection antibody.
Surgical procedures
For single brain injections, mice were anesthetized with
ketamine/xylazine (Sigma) and placed in a stereotaxic
apparatus (David Kopf Instruments, Tujunga, CA, USA).
2 μL vehicle (PBS) or 2 μL 10 mM apoE dimer peptide in
PBS was injected into the dorsal hippocampus (AP = -1.0
mm, ML = +1.8 mm, DV = -2.2 mm) from the bregma
according to Paxinos and Watson (1998). Solutions were
continuously delivered over a duration of 4 minutes.
After completion of each injection, the cannula was left in
place for an additional 4 min in order to accomplish
quantitative diffusion of the volume delivered. At the
appropriate survival times, animals were sacrificed, and
the hippocampus and surrounding cortex were dissected
and collected.
Statistical analysis
Experiments were repeated a minimum of three times
unless otherwise noted. All data were analyzed using
ANOVA with Graphpad Prism 5 software, using Tukey's
multiple comparison test for post hoc analyses with sig-
nificance determined as p < 0.05. Descriptive statistics
are displayed as mean ± SEM.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AC, SD, and MP performed structural analyses on the chemical compounds;
SSM, JRC, HSH, JAT, LWB, and GCD conducted experiments. SSM, MP, and HSH
prepared the manuscript, GWR, RST, and DTSP provided resources and valuable
scientific insight, and MP and HSH supervised the overall project. All authors
have read and approved the final manuscript.
Acknowledgements
This work is supported by NIH AG 032330 (HSH), NIH AG 032330-02S1 (HSH), 
NIH AG 034253 (HSH), NIH AG 026478 (RST) and NIH AG014473 (GWR). JAT and 
LWB were supported by a grant to Georgetown University from the Under-
graduate Program at the Howard Hughes Medical Institute. We thank Dr. Paul 
Matthews (Nathan Kline Institute, New York, NY) for the C1/6.1 antibody.
Author Details
1Department of Neuroscience, Georgetown University, 3970 Reservoir Rd. NW, 
Washington, DC 20057, USA, 2Drug Discovery and Drug Therapeutics, 
Georgetown University, 3970 Reservoir Rd. NW, Washington, DC 20057, USA, 
3Department of Neurology, Georgetown University, 4000 Reservoir Rd. NW, 
Washington, DC 20057, USA, 4Department of Pharmacology, Georgetown 
University Medical Center, 3900 Reservoir Rd. NW, Washington, DC 20057, USA 
and 5Department of Neurology, Washington University, St. Louis, MO 63110, 
USA
References
1. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana 
Rao BS, Chattarji S, Kelleher RJ, Kandel ER, Duff K, et al.: Loss of presenilin 
function causes impairments of memory and synaptic plasticity 
followed by age-dependent neurodegeneration.  Neuron 2004, 
42:23-36.
2. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, 
Fahrenholz F: Constitutive and regulated alpha-secretase cleavage of 
Alzheimer's amyloid precursor protein by a disintegrin 
metalloprotease.  Proc Natl Acad Sci USA 1999, 96:3922-3927.
3. Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW: Maturation and 
endosomal targeting of beta-site amyloid precursor protein-cleaving 
enzyme. The Alzheimer's disease beta-secretase.  J Biol Chem 2000, 
275:33729-33737.
4. Roses AD: On the discovery of the genetic association of 
Apolipoprotein E genotypes and common late-onset Alzheimer 
disease.  J Alzheimers Dis 2006, 9:361-366.
5. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K: Apolipoprotein E 
immunoreactivity in cerebral amyloid deposits and neurofibrillary 
tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-
Jakob disease.  Brain Res 1991, 541:163-166.
6. Naslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlstrom AR, 
Bogdanovic N, Gandy SE, Lannfelt L, Terenius L, Nordstedt C: 
Characterization of stable complexes involving apolipoprotein E and 
the amyloid beta peptide in Alzheimer's disease brain.  Neuron 1995, 
15:219-228.
7. LaDu MJ, Lukens JR, Reardon CA, Getz GS: Association of human, rat, and 
rabbit apolipoprotein E with beta-amyloid.  J Neurosci Res 1997, 49:9-18.
8. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, 
Smith JD, Ladu MJ, Rostagno A, et al.: Lipidation of apolipoprotein E 
influences its isoform-specific interaction with Alzheimer's amyloid 
beta peptides.  Biochem J 2000, 348(Pt 2):359-365.
9. Dodart JC, Bales KR, Johnstone EM, Little SP, Paul SM: Apolipoprotein E 
alters the processing of the beta-amyloid precursor protein in 
APP(V717F) transgenic mice.  Brain Res 2002, 955:191-199.
10. Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, Holtzman DM, 
Bu G: Apolipoprotein E and low density lipoprotein receptor-related 
protein facilitate intraneuronal Abeta42 accumulation in amyloid 
model mice.  J Biol Chem 2006, 281:36180-36186.
11. Beffert U, Aumont N, Dea D, Lussier-Cacan S, Davignon J, Poirier J: Beta-
amyloid peptides increase the binding and internalization of 
apolipoprotein E to hippocampal neurons.  J Neurochem 1998, 
70:1458-1466.
12. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, 
Lamb B, Willson TM, Collins JL, et al.: ApoE promotes the proteolytic 
degradation of Abeta.  Neuron 2008, 58:681-693.
13. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, 
Malkani S, Bales KR, Paul SM: Apolipoprotein E promotes astrocyte 
colocalization and degradation of deposited amyloid-beta peptides.  
Nat Med 2004, 10:719-726.
14. Zlokovic BV: New therapeutic targets in the neurovascular pathway in 
Alzheimer's disease.  Neurotherapeutics 2008, 5:409-414.
15. Moulder KL, Narita M, Chang LK, Bu G, Johnson EM Jr: Analysis of a novel 
mechanism of neuronal toxicity produced by an apolipoprotein E-
derived peptide.  J Neurochem 1999, 72:1069-1080.
16. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, 
Schmechel D, Wisniewski T, Frangione B, Roses AD, et al.: Apolipoprotein 
E associates with beta amyloid peptide of Alzheimer's disease to form 
novel monofibrils. Isoform apoE4 associates more efficiently than 
apoE3.  J Clin Invest 1994, 94:860-869.
17. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-
Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD: Binding of 
human apolipoprotein E to synthetic amyloid beta peptide: isoform-
specific effects and implications for late-onset Alzheimer disease.  Proc 
Natl Acad Sci USA 1993, 90:8098-8102.
18. Dodart JC, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, Paul 
SM: Gene delivery of human apolipoprotein E alters brain Abeta 
burden in a mouse model of Alzheimer's disease.  Proc Natl Acad Sci USA 
2005, 102:1211-1216.
19. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM: 
Human and murine ApoE markedly alters A beta metabolism before 
Received: 16 February 2010 Accepted: 20 April 2010 
Published: 20 April 2010
This article is available from: http://www.molecularneurodegeneration.com/content/5/1/16 © 2010 Minami et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Molecular Neurodegeneration 2010, 5:16Minami et al. Molecular Neurodegeneration 2010, 5:16
http://www.molecularneurodegeneration.com/content/5/1/16
Page 12 of 12
and after plaque formation in a mouse model of Alzheimer's disease.  
Neurobiol Dis 2002, 9:305-318.
20. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, 
Mackey B, Olney J, McKeel D, Wozniak D, Paul SM: Apolipoprotein E 
isoform-dependent amyloid deposition and neuritic degeneration in a 
mouse model of Alzheimer's disease.  Proc Natl Acad Sci USA 2000, 
97:2892-2897.
21. Irizarry MC, Deng A, Lleo A, Berezovska O, Von Arnim CA, Martin-
Rehrmann M, Manelli A, LaDu MJ, Hyman BT, Rebeck GW: Apolipoprotein 
E modulates gamma-secretase cleavage of the amyloid precursor 
protein.  J Neurochem 2004, 90:1132-1143.
22. Ye S, Huang Y, Mullendorff K, Dong L, Giedt G, Meng EC, Cohen FE, Kuntz 
ID, Weisgraber KH, Mahley RW: Apolipoprotein (apo) E4 enhances 
amyloid beta peptide production in cultured neuronal cells: apoE 
structure as a potential therapeutic target.  Proc Natl Acad Sci USA 2005, 
102:18700-18705.
23. He X, Cooley K, Chung CH, Dashti N, Tang J: Apolipoprotein receptor 2 
and X11 alpha/beta mediate apolipoprotein E-induced endocytosis of 
amyloid-beta precursor protein and beta-secretase, leading to 
amyloid-beta production.  J Neurosci 2007, 27:4052-4060.
24. Hoe HS, Rebeck GW: Regulation of ApoE receptor proteolysis by ligand 
binding.  Brain Res Mol Brain Res 2005, 137:31-39.
25. Hoe HS, Pocivavsek A, Dai H, Chakraborty G, Harris DC, Rebeck GW: Effects 
of apoE on neuronal signaling and APP processing in rodent brain.  
Brain Res 2006, 1112:70-79.
26. Laskowitz DT, McKenna SE, Song P, Wang H, Durham L, Yeung N, 
Christensen D, Vitek MP: COG a novel apolipoprotein E-based peptide, 
improves functional recovery in a murine model of traumatic brain 
injury.  J Neurotrauma 2007, 24:1093-1107.
27. Hoe HS, Harris DC, Rebeck GW: Multiple pathways of apolipoprotein E 
signaling in primary neurons.  J Neurochem 2005, 93:145-155.
28. Lynch JR, Wang H, Mace B, Leinenweber S, Warner DS, Bennett ER, Vitek 
MP, McKenna S, Laskowitz DT: A novel therapeutic derived from 
apolipoprotein E reduces brain inflammation and improves outcome 
after closed head injury.  Exp Neurol 2005, 192:109-116.
29. Li FQ, Sempowski GD, McKenna SE, Laskowitz DT, Colton CA, Vitek MP: 
Apolipoprotein E-derived peptides ameliorate clinical disability and 
inflammatory infiltrates into the spinal cord in a murine model of 
multiple sclerosis.  J Pharmacol Exp Ther 2006, 318:956-965.
30. Pocivavsek A, Burns MP, Rebeck GW: Low-density lipoprotein receptors 
regulate microglial inflammation through c-Jun N-terminal kinase.  
Glia 2009, 57:444-453.
31. Hoe HS, Cooper MJ, Burns MP, Lewis PA, Brug M van der, Chakraborty G, 
Cartagena CM, Pak DT, Cookson MR, Rebeck GW: The metalloprotease 
inhibitor TIMP-3 regulates amyloid precursor protein and 
apolipoprotein E receptor proteolysis.  J Neurosci 2007, 27:10895-10905.
32. Parvathy S, Hussain I, Karran EH, Turner AJ, Hooper NM: Cleavage of 
Alzheimer's amyloid precursor protein by alpha-secretase occurs at the 
surface of neuronal cells.  Biochemistry 1999, 38:9728-9734.
33. Cole GM, Ard MD: Influence of lipoproteins on microglial degradation 
of Alzheimer's amyloid beta-protein.  Microsc Res Tech 2000, 50:316-324.
34. Xia W, Zhang J, Kholodenko D, Citron M, Podlisny MB, Teplow DB, Haass C, 
Seubert P, Koo EH, Selkoe DJ: Enhanced production and 
oligomerization of the 42-residue amyloid beta-protein by Chinese 
hamster ovary cells stably expressing mutant presenilins.  J Biol Chem 
1997, 272:7977-7982.
doi: 10.1186/1750-1326-5-16
Cite this article as: Minami et al., ApoE mimetic peptide decreases A? pro-
duction in vitro and in vivo Molecular Neurodegeneration 2010, 5:16